PAVmed Inc. – Consensus Indicates Potential 187.0% Upside

Broker Ratings

PAVmed Inc. with ticker code (PAVM) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 5.25 and 5 with the average target price sitting at 5.08. With the stocks previous close at 1.77 this now indicates there is a potential upside of 187.0%. The 50 day MA is 1.87 and the 200 moving average now moves to 1.97. The market cap for the company is $95m. Find out more information at:

PAVmed Inc. operates as a medical device company in the United States. The company’s lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index